Our Mission
We are leveraging a $19 million investment from the U.S. military to develop PM-208, a drug that treats capillary compression—a major, unsolved problem in hemorrhagic shock and other ischemic conditions, including acute kidney injury, cardiac bypass dysfunction, and ischemic reperfusion injury. PM-208 is a patent-protected drug with a simple formulation, a straightforward mechanism of action, and a strong preclinical safety profile. It has the potential to help more than 4 million patients annually in the U.S., with a market opportunity exceeding $10 billion.
Our Team
In addition to investor capital,
Perfusion Medical has received funding from
Perfusion Medical works with a group of highly experienced contract research organizations and partners.
Accelerator programs and recognition
